Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on December 18, 2012. The report addresses a regulatory notice regarding the company's compliance with NASDAQ listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on stock price compliance issues.
Material Changes
- Delisting Notice: The company received a second letter from NASDAQ stating it failed to regain compliance with Listing Rule 5550(a)(2) by the December 17, 2012 deadline.
- Compliance Deficiency: The company failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days within the 180-day grace period.
- Current Status: The company has requested a hearing with the NASDAQ Hearings Panel. This request stays the delisting determination pending the hearing outcome.
Guidance, Outlook, and Risks
- Remediation Plan: The company intends to cure the deficiency by effecting a reverse stock split if necessary. To regain compliance, the stock must close at $1.00 or more for ten consecutive business days.
- Risks: There is no assurance the Hearings Panel will grant continued listing. If the company fails to gain a further extension, the stock is subject to immediate delisting.
- Forward-Looking Statements: The report includes standard disclaimers that actual outcomes may differ materially from expectations due to risks outlined in the company's Form 10-K.
Investor Verification Checklist
- Verify the date and outcome of the scheduled NASDAQ Hearings Panel.
- Confirm whether the company has filed a proposal for a reverse stock split.
- Monitor the daily closing bid price to see if it reaches the $1.00 threshold for ten consecutive business days.
- Review the company's most recent Form 10-K for detailed financial risks and liquidity status not included in this 8-K.